HypertrofickÃ¡ kardiomyopatie â prof. MUDr. Josef Veselka, CSc ...

More documents

Recommendations

Info

ASA: Multicenter European StudyBaselinen=421Follow‐upn=394 P valueAge, years – median (IQR) 59 (48‐67)Alcohol volume, ml – median (IQR) 1.5 (1‐2)Left ventricular outflow gradient, mmHg 89 (60‐130) 21.5 (11‐42)
ASA: Multicenter European StudyMajor complications and therapeutic interventions during early post‐ASA periodDeath, n (%) 3 (0.7)Resuscitation for complete heart block, n (%) 5 (1.2)Syncope, n (%) 1 (0.2)Pericardial effusion or cardiac tamponade, n (%) 2 (0.4)No-reflow phenomenon, n (%) 1 (0.2)Alcohol leakage into the left anterior descending artery, n (%) 1 (0.2)Pulmonary embolism, n (%) 1 (0.2)Post-interventional sustained ventricular tachycardia/fibrillation, n (%) 3 (0.7)Non-sustained ventricular tachycardia, n (%) 12 (2.9)Post-interventional cardiac failure, n (%) 1 (0.2)Implantation of cardioverter-defibrillator for post-ASA ventricular arrhythmia, n (%) 1 (0.2)Implantation of cardioverter-defibrillator in primary prevention of sudden death, n (%) 7 (1.7)Electrical cardioversion for atrial fibrillation, n (%) 1 (0.2)Radiofrequency catheter ablation for supraventricular tachycardia, n (%) 1 (0.2)Pacemaker implantation for hypersensitive carotid sinus, n (%) 1 (0.2)<strong>Veselka</strong> J et al. JACC abstr. 2012
Page 1:
Hypertrofická kardiomyopatiewww.ka
Page 4 and 5:
Definice HCM• Klinická - primár
Page 6 and 7:
Genetika HCM
Page 8 and 9:
FenokopieBos JM et al. JACC 2009
Page 10 and 11:
Prevalence and spectrum of HCM‐as
Page 12 and 13: Patologicko -anatomický obraz
Page 14 and 15: Mitrální chlopeňMaron MS et al.
Page 16 and 17: Anomalies of PMsDesai M et al. 2008
Page 18 and 19: Apical hypertrophy
Page 21 and 22: Echokardiografická diagnostika•
Page 31 and 32: Provokace obstrukce• Snížený p
Page 33 and 34: Pravostranná obstrukce
Page 35 and 36: Mitrální regurgitace u HCMPříč
Page 37 and 38: Dif. dg. HCM a „atletické srdce
Page 39 and 40: Doporučení pro dg. a sledování
Page 41 and 42: Katetrizační vyšetřeníDříve
Page 43 and 44: GLE
Page 45: Prognóza• Mortalita/rok:- Celkov
Page 48 and 49: Riziko NS dle US Guidelines
Page 50 and 51: Doporučení týkající se fyzick
Page 52 and 53: ICD and SCD in HCMMaron BJ et al.,
Page 54 and 55: Medikamentózní terapie• Betablo
Page 56 and 57: Real‐time imaging
Page 58 and 59: Změna ablační techniky• „Sup
Page 60 and 61: Low‐dose ASA
Page 64 and 65: ASA: Multicenter European StudyComp
Page 66 and 67: Dochází ke snížení PG,remodela
Page 68 and 69: ERASH(Endocardial Radiofrequency Ab
Page 71 and 72: Myektomie
Page 73 and 74: Kardiostimulace• Metoda vzniklá
Page 75 and 76: Výkonnost po KSMaron BJ, Circulati
Page 77: Cardiomyopathies ‐ From BasicRese
show all

HypertrofickÃ¡ kardiomyopatie â prof. MUDr. Josef Veselka, CSc ...

Create successful ePaper yourself

Delete template?

Save as template?

HypertrofickÃ¡ kardiomyopatie â prof. MUDr. Josef Veselka, CSc ...